Commercial Strategies and Sustainability: A Year of Growth for Eurospital in 2024
Pubblicato il
“Strengthening our sustainable growth strategies and continuous business innovation have been the winning cards behind another successful year for Eurospital. With a turnover of €38.5 million, driven by pharmaceutical sales, we close 2024 with significant achievements in new product launches and innovative projects aimed at renewing our portfolio — such as the creation of the new Special Nutrition Division,” said Michele Kropf, President and CEO of Eurospital. “I want to thank everyone — employees and stakeholders — for helping achieve these results. We look ahead to another year full of opportunities to continue creating value together.”
Diagnostics Division
In response to the ongoing transformation of the post-COVID market, sales remained stable, supported by both traditional diagnostics — such as tests for celiac disease and calprotectin — and new developments across various product lines.
In the field of Molecular Biology, two new diagnostic tests were launched to help prevent major diseases:
- Eu-Gen FII/FV Type, which detects the main genetic variants associated with thrombophilia, a condition that increases the risk of thrombotic events;
- Eu-Gen MTHFR Dual-Type, which identifies genetic mutations that impair the proper function of the MTHFR enzyme — crucial in regulating homocysteine levels in the blood, an excess of which is linked to a higher risk of cardiovascular disease.
In the Gastroenterology line, the new Universal solution was launched within the EasyCal® family of diagnostic devices. It allows for the simultaneous detection of three key gastrointestinal markers from a single sample, simplifying laboratory procedures.
A key commercial milestone was the opening of the South American market, with the launch of EU-Turbo Analyzer in Colombia and Ecuador — a turbidimetric instrument enabling fast and easy quantitative analysis of fecal markers relevant to gastrointestinal diseases.
Pharmaceutical Division
Sales recorded significant growth in 2024, driven by the strong performance of infusion solutions, reaffirming Eurospital’s leadership in this market.
Promising results also came from the new Personal Care line, dedicated to the personal care of adults and children. The line was expanded with new products across multiple therapeutic areas, in response to market trends, lifestyle changes, and consumers’ growing awareness of the importance of staying healthy.
Sales also increased for Eurospital’s long-standing children’s brands:
- Haliborange, the vitamin D supplement line;
- Fiordinaso, the gentle nasal rinse device;
- And the distributed products launched in 2023:
- LactoSolution, a food supplement for lactose intolerance, and
- Waterdrop microdrink cubes.
Thanks to a new commercial partnership, the distribution of Glassio reading glasses also began in 2024.
Special Nutrition Division
The launch of the Apromé line of low-protein foods in the second half of 2024 marked a strategic turning point for Eurospital, which established the new Special Nutrition Division, featuring over 150 products designed for individuals requiring gluten-free and low-protein diets.
Piaceri Mediterranei experienced strong growth and confirmed its position as the third-leading gluten-free brand in the pharmacy channel.
With the launch of Piacerini — a new line of delicious sweet snacks — the already extensive product assortment, perfected by Eurospital through more than 15 years of research, is set to expand further in 2025 with an additional 10 new items.
Many of these products are VEGANOK-certified, the ethical standard for items entirely free of animal-derived ingredients.
The innovative characteristics of Apromé products — formulated for those who need to follow a diet low in protein, sodium, phosphorus, potassium, and phenylalanine — received very positive feedback from industry professionals. Market reach will be further enhanced through new collaborations in the medical-scientific field and the launch of 10 additional low-protein food products.
“Sustainable innovation is a longstanding tradition at Eurospital, and we pursue it by diversifying our strategies. In 2024, we invested 7% of the Diagnostics Division’s revenue into 15 research projects in gastroenterology and molecular biology, engaging 10% of our workforce. These professionals collaborate daily with international centers of excellence to identify winning solutions,” said Massimiliano Kropf, CEO of Eurospital.
“Moreover, the agility of our commercial strategies across all business areas continues to drive changes in our product portfolio — changes that companies like Eurospital are able to anticipate thanks to constant focus on customer needs and market trends.”
ESG Topics (Environment, Social, Governance)
In 2024, Eurospital published its second Sustainability Report, which not only highlights concrete achievements in environmental, social, and governance performance, but also expands its reporting by integrating the Sustainable Development Goals (SDGs) into the company’s strategy — a clear sign of the growing commitment to measurable initiatives.
In the environmental sector, investments in energy efficiency led to significant savings. In 2024, the photovoltaic system was upgraded, now consisting of more than 800 units, which increased KWh production by 36%. Even greater results in energy self-sufficiency are expected in 2025.
Additional ongoing efforts focus on reducing the use of materials to minimize the environmental impact of operations and limit plastic usage.
2024 also saw the launch of major initiatives for employee well-being and engagement, as Eurospital’s people have always been the driving force behind its sustainable growth. In addition to continued investment in skill development, the company increased team-building events and internal communications related to health, culture, and art initiatives.
Corporate volunteering was also introduced, offering Eurospital employees the opportunity to support the local community during working hours as an act of solidarity.
“The progress we made last year was fueled by the innovative spirit that has defined Eurospital since its founding,” concludes Giulia Kropf, Board Member and Technical Director of Eurospital.
“Whether we look at the commercial strategies in our three Business Areas, our research and development activities with partners, our renewed environmental and social responsibility policies, or our ongoing dialogue with customers, patients, and consumers — everything reflects the team’s deep commitment to working with ethics, transparency, and great ambition, in pursuit of our mission to improve people’s quality of life.”